Your Health, We Care
Release date: 2024-08-27 14:55:42 Recommended: 148
Alpelisib was approved by the FDA in May 2019 for use in combination with fulvestrant to inhibit tumor progression in postmenopausal women and men with advanced breast cancer with HR/HER2- and PIK3CA mutations.
Clinical trial data suggests that patients need to be aware of the following when using the drug.
During treatment, watch for symptoms of diarrhea or colitis, such as abdominal pain, mucus or bloody stools. If symptoms are severe, the dose may need to be adjusted or the drug may need to be stopped. If diarrhea occurs, antidiarrheal therapy should be started immediately, fluid intake should be increased, and the doctor should be notified promptly.
If severe skin reactions (eg, SCARs) occur, the drug should be discontinued immediately and a dermatologist should be consulted. A diagnosis of SCAR requires permanent discontinuation of the drug. If the diagnosis is not confirmed, the dose may need to be adjusted and treatment with topical corticosteroids or oral antihistamines may be required.
Patients should read the package insert carefully for important precautions. In addition to this, patients should also pay attention to the recommended dosage of the drug.
It is important for doctors and patients to know the dosage and dosage of the drug, according to the drug label:
The standard dose of Alpelisib is 300 mg, which is two 150 mg film-coated tablets. Take once a day, preferably with a meal, to improve absorption.
Continue to use Alpelisib until the disease progresses or serious side effects occur. Patients should be monitored closely for response during treatment.
Throughout treatment, make sure to use Alpelisib as recommended and as directed by your doctor, paying attention to any possible adverse effects.
There may be some adverse effects associated with drug use, which patients need to focus on before using the drug.
The use of the drug may lead to significant weight loss, affecting overall health and nutritional status. The cause of weight change needs to be assessed and appropriate interventions applied.
Medications can cause a drop in blood calcium levels, triggering a decrease in bone density or muscle cramps. Calcium supplementation or modification of treatment regimens may help alleviate these problems.
Patients are advised to monitor their weight and serum calcium levels regularly, and to take timely measures and adjust treatment regimens if symptoms occur.
[Warm tips] During the treatment, patients should pay attention to the changes in weight and blood calcium, take the medicine on time and in accordance with the doctor's instructions, check regularly and communicate with the doctor to ensure that the health condition is properly managed.
